Skip to main content
. 2016 Mar 7;7(15):20381–20394. doi: 10.18632/oncotarget.7953

Figure 7. Low expression of miR-148a is associated with poor prognosis of breast cancer patients.

Figure 7

(A) Levels of miR-148a expression were determined in primary (Tumor) and metastatic (Mets) tumor samples from breast cancer patients [19] and normalized to the levels of miR-148a in primary tumors. Error bars are standard errors (n = 7). P value was calculated with unpaired, two-tailed t test. (B–E) Kaplan-Meier curves for disease-specific survival for high and low expression of miR-148a in breast cancer patients with metastasis (B) or without detectable metastasis (C). Basal subtype (D) and LumB subtype (E) of patients with metastasis were further analyzed using Kaplan-Meier curves for high and low expression of miR-148a. Data was extracted from METABRIC data [55]. Survival time was cropped at 15 years. (F–H) Kaplan-Meier curves for distant-relapse free survival for high and low expression of miR-148a in total breast cancer patients (F), ER-negative patients (G), and ER-positive patients (H). Data was extracted from GSE22220. B-H, P values were calculated with Log-rank (Mantel-Cox) test. Hazard ratios were calculated with the method of Mantel-Haenszel).